<DOC>
	<DOCNO>NCT02322606</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics TAK-137 healthy male subject .</brief_summary>
	<brief_title>A Phase 1 , Single Multiple Dose Study TAK-137</brief_title>
	<detailed_description>This study phase 1 , randomize , placebo-controlled , double-blind , multiple ascend dose study Japanese healthy male participant assess safety , tolerability PK follow single multiple oral dos TAK-137 . This study compose 2 part , Single Dose part ( Cohorts 1 3 ) Multiple Dose part ( Cohorts 4 6 ) . Up 48 participant enrol . Single dose part ( Cohorts 1-3 ) : Single Dose , 3 dose level , Placebo-Controlled , Randomized , Double-Blind . Each cohort include 8 participant . Participants randomly assign either TAK-137 placebo treatment group within cohort allocation ratio 6:2 . The plan dose level study 5 , 10 20 mg . The principal investigator consult sponsor medical specialist need determine go/no-go next cohort.. The dose Cohorts 3 may reduce 2 mg/day instead 20 mg/day principal investigator , consultation sponsor , considers appropriate . Multiple dose Part ( Cohorts 4-6 ) : Multiple Dose , 3 dose level , Placebo-Controlled , Randomized , Double-Blind . Each cohort include 8 participant . Participants randomly assign either TAK-137 placebo treatment group within cohort allocation ratio 6:2 . The plan dose level study 5 , 10 , 15 mg , however Cohort 5 6 , dose level may amend base safety tolerability data obtain either Cohorts 1-4 study emerge data multiple rise dose study conduct , parallel United Sates ( TAK-137_102 ) . The principle investigator , consultation sponsor , determine dose level cohorts 5 6 ( Not exceed 20mg ) .</detailed_description>
	<criteria>Participant eligibility determine accord follow criterion prior entry study : In opinion investigator , participant capable understand comply protocol requirement . The participant sign date write , ICF require privacy authorization prior initiation study procedure . The participant healthy Japanese adult male volunteer . The participant 20 45 year age time informed consent . The participant body weight least 50 kg body mass index ( BMI ) 18.5 24.9 kg/m2 time screen baseline ( Day 1 ) . A male participant sexually active female partner childbearing potential agrees use adequate contraception sign ICF 12 week last dose . Any participant meet follow criterion qualify entry study : The participant receive investigational drug within 30 day prior first study drug administration . The participant receive TAK137 previous clinical study . The participant immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . The participant uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic endocrine disease abnormality may impact ability participant participate potentially confound study result . The participant previously seizure convulsion ( lifetime ) , include absence seizure febrile convulsion The participant history psychiatric disorder . The participant know hypersensitivity medication ( ) food ( ) . The participant positive result urine drug screen test screening . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior screen unwilling agree abstain alcohol drug throughout study period . The participant take excluded medication , supplement , food product list Excluded Medications Dietary Products screen period , require medication food study . The participant intend donate sperm sign ICF 12 week last dose . The participant current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( i.e. , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention , [ e.g . gastrectomy , cholecystectomy , etc. ] ) . The subject history cancer . The subject positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody/antigen , serological reaction syphilis screen . The subject poor peripheral venous access . The subject undergone whole blood collection least 200 mL within 4 week ( 28 day ) least 400 mL within 12 week ( 84 day ) prior first study drug administration . The participant undergone whole blood collection least 800 mL total within 52 week ( 364 day ) prior first study drug administration . The participant undergone blood component collection within 2 week ( 14 day ) prior first study drug administration . The participant clinically significant ECG abnormality time screen baseline ( Day 1 ) . The participant abnormal screen baseline ( Day 1 ) laboratory value suggest clinically significant underlying disease , participant follow lab abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5 Ã— upper limit normal ( ULN ) . The participant abnormal EEG screen The participant risk suicide base investigator 's determination . The participant , opinion investigator , unlikely comply protocol unsuitable reason .</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>